Clarus Therapeutics Holdings, Inc.

CRXTCIK 0001817944 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 28, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0047

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Clarus Therapeutics Holdings, Inc.

Name	Roles	Filings
Hernandez Joseph	Director	2
Amory John Kenneth	Director	1
Cermak Elizabeth	Director	1
Murphy Kimberly M	Director	1
Prygocki Mark A Sr	Director	1

Showing 1-5 of 14

Per pagePage 1 of 3Next

All filings

7 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
Jun 9, 2022	Cermak Elizabeth Director	AGrant	1,922	$0.00	$0
Jun 9, 2022	Hernandez Joseph Director	AGrant	1,922	$0.00	$0
Jun 9, 2022	Amory John Kenneth Director	AGrant	1,922	$0.00	$0
Jun 9, 2022	Murphy Kimberly M Director	AGrant	1,922	$0.00	$0
Jun 9, 2022	Prygocki Mark A Sr Director	AGrant	1,922	$0.00	$0

Showing 1-5 of 7

Per pagePage 1 of 2Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value